Kristin Highland, MD of the Cleveland Clinic discusses the results for the ongoing SENSCIS-ON trial testing nintedanib to treat interstitial lung disease in patients with systemic sclerosis. 

Systemic sclerosis is a rare autoimmune disease that is associated with immune dysregulation, microvascular damage, and organ fibrosis.  A common manifestation of systemic sclerosis is an interstitial lung disease which is a leading cause of death in patients with systemic sclerosis. Interstitial lung disease often occurs early in the course of systemic sclerosis, so any treatment that can slow the progression of interstitial lung disease can dramatically improve patients’ outlook and quality of life. Such is the case with nintedanib, which was shown in the SENSCIS trial to attenuate the decline in forced vital capacity by 44%. 

More recently, interim results of the ongoing open label extension study (SENSCIS-ON trial) continued to show the drug to be as safe and effective as observed in the original trial.

To learn more about this and other rare pulmonary conditions, visit